Get the Stockscreener App
5.54
4.53%
0.24
Cns Pharmaceuticals Inc stock is traded at $5.54, with a volume of 9,741.
It is up +4.53% in the last 24 hours and down -16.06% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$5.30
Open:
$5.6016
24h Volume:
9,741
Relative Volume:
0.54
Market Cap:
$3.44M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.0783
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
+5.52%
1M Performance:
-16.06%
6M Performance:
-47.75%
1Y Performance:
-91.67%
1-Day Range:
$5.37
$5.7364
1-Week Range:
$5.18
$5.7364
52-Week Range:
$4.93
$114.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.54 | 3.29M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNS Pharmaceuticals Inc. (CNSP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 0.5% – Here’s Why - Defense World
Aug Reactions: How CNS Pharmaceuticals Inc stock performs in rate cut cycles2025 Top Gainers & Capital Efficient Trading Techniques - moha.gov.vn
CNS Pharmaceuticals names Rami Levin as new CEO following John Climaco’s departure - MSN
Whats Driving Tourism Finance Corporation of India Limited Stocks Recent Momentum Key TrendsCandlestick Trading Patterns & High Return Capital Strategies - earlytimes.in
Why CNS Pharmaceuticals Inc. stock is popular among millennialsJuly 2025 Update & Free Risk Controlled Daily Trade Plans - Улправда
Will CNS Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда
Is CNS Pharmaceuticals Inc. stock positioned well for digital economyQuarterly Earnings Report & High Conviction Buy Zone Picks - Улправда
CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 19, 2025) - GuruFocus
CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 18, 2025) - GuruFocus
CNS Pharmaceuticals appoints Rami Levin as new CEO, replacing Climaco By Investing.com - Investing.com South Africa
CNS Pharmaceuticals Announces New CEO Appointment - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Rami Levin as President and CEO - Digital Journal
CNS Pharmaceuticals Appoints Rami Levin as CEO to Advance Brain Cancer Pipeline - citybuzz -
CNS Pharmaceuticals shares dip after CEO departure announcement - MSN
CNS Pharmaceuticals appoints Rami Levin as CEO, John Climaco resigns By Investing.com - Investing.com Australia
CNS Pharmaceuticals appoints Rami Levin as CEO effective Jan 1, 2026 - marketscreener.com
CNS Pharmaceuticals stock falls after CEO steps down - Investing.com India
CNS Pharmaceuticals stock falls after CEO steps down By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals appoints Rami Levin as CEO, John Climaco resigns - Investing.com
CNS Pharmaceuticals Announces CEO Transition - TradingView — Track All Markets
CNS Pharmaceuticals (CNSP) appoints new CEO Rami Levin and outlines Climaco severance - Stock Titan
CNS Pharmaceuticals (CNSP) Appoints New CEO - GuruFocus
CNS Pharmaceuticals appoints Rami Levin as new CEO, replacing Climaco - Investing.com India
Brain cancer drug developer taps new CEO with global track record - Stock Titan
CNS Pharmaceuticals Earnings Notes - Trefis
Cycle buying Applied Therapeutics to develop CNS drugs - BioWorld MedTech
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 7th Annual CNS Delivery SummitSlideshow - Seeking Alpha
Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities CNS Therapeutics Virtual Conference 2025, Dec-08-2025 12 - marketscreener.com
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast - Digital Journal
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 (PRAX) - Seeking Alpha
CNS Pharmaceuticals CEO Outlines Strategy to Target Glioblastoma by Overcoming Blood-Brain Barrier - citybuzz
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Will CNS Pharmaceuticals Inc. stock gain from lower inflationGold Moves & High Accuracy Trade Alerts - Newser
CNS Pharma (CNSP) Stock Analysis Report | Financials & Insights - Benzinga
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
CNS Pharmaceuticals, Inc. (CNSP) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Alector to Participate in the Bank of America CNS Therapeutics Conference - Yahoo Finance
What analysts say about CNS Pharmaceuticals Inc stockGrowth vs. Value Investing & High Profit Investment Ideas - earlytimes.in
Where Analysts See Bemco Hydraulics Limited Stock by YearEndRisk-Reward Ratio Analysis & Free Rapid Return Acceleration - earlytimes.in
Bank of America CNS Therapeutics Virtual Conference - marketscreener.com
CNS Pharmaceuticals, Inc.Common Stock (NQ: CNSP - Markets Financial Content
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - The Manila Times
CNS Pharmaceuticals Increases Authorized Shares for Growth - The Globe and Mail
CNS Pharmaceuticals shareholders approve share increases and board elections at annual meeting - Investing.com Australia
CNS Pharmaceuticals shareholders approve share increases and board elections at annual meeting By Investing.com - Investing.com South Africa
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):